SecBot SecBot
PRESS-RELEASE ·Filed May 30, 2026

COGT

Cogent Biosciences, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The PEAK data and Priority Review are strong catalysts; the stock may re-rate upward as the market prices in a high-probability approval and commercial launch in 2H 2026. Traders should watch for the PDUFA date (Nov 30, 2026) and any updates on the first-line exon 9 cohort.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$34.81
T+0 close · May 30, 2026 · via day close
Latest settled
+5.72%
T+60 · $36.80
Vs SPY
+4.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $34.81entry
  2. T+1 · 6mo ago −5.89%α −6.03% · $32.76
  3. T+5 · 5mo ago −10.89%α −8.14% · $31.02
  4. T+20 · 5mo ago +11.18%α +12.47% · $38.70
  5. T+60 · 3mo ago +5.72%α +4.49% · $36.80

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cogent Biosciences reported highly positive Phase 3 PEAK trial results for bezuclastinib in combination with sunitinib in second-line GIST, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (median PFS 16.5 months vs 9.2 months, HR=0.50, p<0.0001) and objective response rate (46% vs 26%) compared to sunitinib alone. The FDA has granted Priority Review for the NDA with a PDUFA date of November 30, 2026, and the company plans to launch later this year. This is a transformative event for the company, as bezuclastinib is its lead asset and the data position it as a potential new standard of care in a large market.

Key Facts

  • Bezuclastinib combination reduced risk of disease progression or death by 50% vs sunitinib alone (HR=0.50, 95% CI: 0.39-0.65, p<0.0001)
  • Median PFS: 16.5 months for combination vs 9.2 months for sunitinib monotherapy
  • Objective response rate: 46% for combination vs 26% for sunitinib
  • FDA granted Priority Review for NDA; PDUFA date November 30, 2026
  • Mean duration of treatment on combination arm estimated at 21.4 months
  • PFS2 (time to progression on next therapy or death) median not reached vs 21 months (HR=0.57)
  • Safety profile generally consistent with sunitinib alone; no unique combination risks observed
  • Initiated new clinical trial of bezuclastinib combination in first-line GIST patients with KIT exon 9 mutations

Financial Impact

Transformative for a $6.0B market cap company with a single lead asset; potential peak sales in GIST could exceed $1B annually given standard-of-care positioning in second-line and expansion into first-line

revenuepipeline valuemarket cap

Risk Factors

  • PDUFA delay or complete response letter (CRL) from FDA, especially on CMC or safety grounds
  • Competition from other KIT inhibitors (e.g., ripretinib, avapritinib) in GIST
  • Commercial execution risk for a first launch by a small biotech
  • Potential transient ALT/AST elevations requiring monitoring and dose management

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
84% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303872

Track record

13 reports on COGT

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
  4. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  5. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  6. Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  7. Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  8. Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  9. May 30, 202624w ago Press Release Bullish 8/10 Viewing Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
  10. May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 30, 2026